Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

Rafael Esteban, Juan A. Pineda, Jose Luis Calleja, Marta Casado, Manuel Rodríguez, Juan Turnes, Luis Enrique Morano Amado, Rosa Maria Morillas, Xavier Forns, Juan Manuel Pascasio Acevedo, Raul J. Andrade, Antonio Rivero, José Antonio Carrión, Sabela Lens, Mar Riveiro-Barciela, Brian McNabb, Gulan Zhang, Gregory Camus, Luisa M. Stamm, Diana M. BrainardG. Mani Subramanian, Maria Buti

Research output: Contribution to journalArticleResearch

29 Citations (Scopus)

Abstract

© 2018 AGA Institute Background & Aims: In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of sofosbuvir and velpatasvir than in patients without cirrhosis. It is unclear whether adding ribavirin to this treatment regimen increases SVRs in patients with genotype 3 HCV infection and cirrhosis. Methods: We performed a phase 2 trial of 204 patients with genotype 3 HCV infection and compensated cirrhosis (mean age 51 ± 7.4 years) at 29 sites in Spain from August 19, 2016 through April 18, 2017. Patients were assigned to groups given sofosbuvir and velpatasvir for 12 weeks (n = 101) or sofosbuvir and velpatasvir plus ribavirin for 12 weeks (n = 103). The primary efficacy end point was SVR12. Results: The overall rates of SVR12 were 91% (92 of 101; 95% CI 84–96) for the sofosbuvir–velpatasvir group and 96% (99 of 103; 95% CI 90–99) for the sofosbuvir–velpatasvir plus ribavirin group. In the sofosbuvir–velpatasvir group, a smaller proportion of patients with baseline resistance-associated substitutions (RASs) in nonstructural protein 5A (NS5A) achieved an SVR12 (84%) than did patients without (96%). In the sofosbuvir–velpatasvir plus ribavirin group, baseline RASs had less effect on the proportion of patients with an SVR12 (96% for patients with baseline RASs; 99% for patients without). The most common adverse events (which occurred in ≥10% of patients) were asthenia (12%) in the sofosbuvir–velpatasvir group and asthenia (27%), headache (24%), and insomnia (12%) in the sofosbuvir–velpatasvir plus ribavirin group. Conclusions: Consistent with findings from previous studies, a high rate of patients (91% and 96%) with genotype 3 HCV infection and compensated cirrhosis achieved an SVR12 with sofosbuvir and velpatasvir, with or without ribavirin. Of patients treated with sofosbuvir and velpatasvir without ribavirin, fewer patients with baseline NS5A RASs achieved an SVR12 compared with patients without baseline NS5A. ClinicalTrials.gov NCT02781558.
Original languageEnglish
Pages (from-to)1120-1127.e4
JournalGastroenterology
Volume155
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • Direct-Acting Antiviral Agent
  • Drug Resistance
  • Outcome

Fingerprint Dive into the research topics of 'Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis'. Together they form a unique fingerprint.

Cite this